PCM
CTMX icon

Penserra Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Penserra Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,490
Closed -$7K – 1408
2021
Q3 		$7K Buy
1,490
+10
+0.7% +$54 ﹤0.01% 1390
2021
Q2 		$9K Buy
1,480
+5
+0.3% +$39 ﹤0.01% 1277
2021
Q1 		$11K Buy
1,475
+415
+39% +$3.29K ﹤0.01% 1023
2020
Q4 		$6K Buy
1,060
+666
+169% +$4.76K ﹤0.01% 970
2020
Q3 		$2K Buy
+394
New +$2.92K ﹤0.01% 905

Other funds holding CTMX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Penserra Capital Management's CTMX Position: Q4 2021 in Review

Penserra Capital Management sold out of CytomX Therapeutics (CTMX) in Q4 2021, closing a stake of 1,490 shares — an estimated $7K sold.

Penserra Capital Management first reported a position in CTMX in Q3 2020 and held it in 5 quarters. The position peaked at $11K in Q1 2021. 110 funds tracked by Wall St. Rank hold CTMX as of Q4 2021.

  • Penserra Capital Management reported no remaining CytomX Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,490 CytomX Therapeutics shares in Q4 2021, an estimated $7K.
  • Penserra Capital Management first reported a position in CytomX Therapeutics in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's CytomX Therapeutics position peaked at $11K in Q1 2021.
  • 110 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.